Article
Chemistry, Medicinal
Yiping Zhang, Longhe Yang, Nannan Zhao, Zhuan Hong, Bing Cai, Qingqing Le, Ting Yang, Lijun Shi, Jianlin He
Summary: The polysaccharide derived from Laminaria japonica can reduce obesity-related abnormalities, modulate gene expressions related to lipid and cholesterol metabolism in the liver, and improve hepatic steatosis caused by a high-fat diet; additionally, it can also improve obesity-related dysbiosis by regulating gut microbiota.
Review
Biochemistry & Molecular Biology
Fuxi Li, Junzhao Ye, Congxiang Shao, Bihui Zhong
Summary: This meta-analysis included 15 case-control studies with a total of 1265 individuals (577 NAFLD patients and 688 controls) and found that Escherichia, Prevotella, and Streptococcus exhibited increased abundance in NAFLD patients, while Coprococcus, Faecalibacterium, and Ruminococcus exhibited decreased abundance. No significant differences were found in the abundance of Bacteroides, Bifidobacterium, Blautia, Clostridium, Dorea, Lactobacillus, Parabacteroides, or Roseburia between NAFLD patients and healthy controls.
LIPIDS IN HEALTH AND DISEASE
(2021)
Article
Plant Sciences
Ji Taek Hong, Min-Jung Lee, Sang Jun Yoon, Seok Pyo Shin, Chang Seok Bang, Gwang Ho Baik, Dong Joon Kim, Gi Soo Youn, Min Jea Shin, Young Lim Ham, Ki Tae Suk, Bong-Soo Kim
Summary: This study showed that in patients with nonalcoholic steatohepatitis, KRG effectively improved liver enzymes and fatigue score by modulating gut-microbiota, while the placebo group had less improvement.
JOURNAL OF GINSENG RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Jai J. Jee, Jiyeon Lim, Sowon Park, Hong Koh, Hye Won Lee
Summary: The study identified heterogenous subpopulations of patients with nonalcoholic fatty liver disease (NAFLD) based on gut microbial composition and potential pathogenic mechanisms. These findings suggest the possibility of personalized treatment for NAFLD patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Gastroenterology & Hepatology
Mijra Koning, Hilde Herrema, Max Nieuwdorp, Abraham S. Meijnikman
Summary: Humans have a diverse gut microbiome, consisting of bacteria, fungi, viruses, and archaea. Patients with NAFLD have an altered gut microbiome and compromised gut barrier function. Preclinical studies suggest that adjusting the gut microbiome could be a promising therapeutic strategy for NAFLD. This overview summarizes the current information on both untargeted techniques (such as probiotics and fecal microbiota transplantation) and targeted microbiome-focused therapies (including engineered bacteria, prebiotics, postbiotics, and phages) for the treatment of NAFLD.
Article
Multidisciplinary Sciences
Kotaro Soeda, Takayoshi Sasako, Kenichiro Enooku, Naoto Kubota, Naoki Kobayashi, Yoshiko Matsumoto Ikushima, Motoharu Awazawa, Ryotaro Bouchi, Gotaro Toda, Tomoharu Yamada, Takuma Nakatsuka, Ryosuke Tateishi, Miwako Kakiuchi, Shogo Yamamoto, Kenji Tatsuno, Koji Atarashi, Wataru Suda, Kenya Honda, Hiroyuki Aburatani, Toshimasa Yamauchi, Mitsuhiro Fujishiro, Tetsuo Noda, Kazuhiko Koike, Takashi Kadowaki, Kohjiro Ueki
Summary: This study suggests that insulin action in the gut may play a protective role in the development of NASH and HCC in diabetes.
NATURE COMMUNICATIONS
(2023)
Article
Pharmacology & Pharmacy
Wenyi Liang, Kun Zhou, Ping Jian, Zihao Chang, Qiunan Zhang, Yuqi Liu, Shuiming Xiao, Lanzhen Zhang
Summary: Ginsenoside extract has shown beneficial effects on high-fat diet-induced nonalcoholic fatty liver disease by modulating gut microbiota, improving gut barrier function, and regulating metabolic inflammation. It also suppressed NF-kappa B/I kappa B signaling activation and promoted hepatic lipolytic genes while inhibiting lipogenic genes. This suggests that ginsenoside extract may be a potential agent for preventing NAFLD through its prebiotic, anti-inflammatory, and energy-regulatory effects.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Laia Bertran, Rosa Jorba-Martin, Andrea Barrientos-Riosalido, Marta Portillo-Carrasquer, Carmen Aguilar, David Riesco, Salome Martinez, Margarita Vives, Fatima Sabench, Daniel Del Castillo, Cristobal Richart, Teresa Auguet
Summary: This study found that OLFMs play a relevant role in NAFLD-related intestinal dysbiosis, with OLFMs in the liver potentially influencing the progression of NAFLD and OLFMs in the jejunum potentially being involved in gut dysbiosis-related inflammatory events.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Agriculture, Multidisciplinary
Shang-Zhen Li, Ning-Ning Zhang, Xing Yang, Tian-Qing Huang, Yang Lin, Zheng-Meng Jiang, Yongxiang Yi, E-Hu Liu
Summary: This study evaluated the effect of nobiletin on NAFLD and determined its underlying mechanism through metabolomics, 16S rRNA gene sequencing, and transcriptomics analysis. The dysbiosis of gut microbiota in NAFLD mice was reversed by nobiletin, which also regulated myristoleic acid metabolism. Treatment with specific bacteria or metabolites displayed a protective effect on liver lipid accumulation. These findings suggest that nobiletin may ameliorate NAFLD by targeting gut microbiota and myristoleic acid metabolism.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
(2023)
Review
Microbiology
Ting-Rui Han, Wen-Juan Yang, Qing-Hua Tan, Shuai Bai, Huang Zhong, Yang Tai, Huan Tong
Summary: Nonalcoholic fatty liver disease (NAFLD) is prevalent worldwide, but there are no approved medications for treatment. Gut microbiota therapy, targeting the gut-liver axis, shows promise in treating NAFLD. This study reviews randomized controlled trials on gut microbiota therapy in NAFLD to evaluate its efficacy and plausibility.
FRONTIERS IN MICROBIOLOGY
(2023)
Review
Cell Biology
Eunju Park, Jin-Ju Jeong, Sung-Min Won, Satya Priya Sharma, Yoseph Asmelash Gebru, Raja Ganesan, Haripriya Gupta, Ki Tae Suk, Dong Joon Kim
Summary: NAFLD is one of the most common and fastest-growing liver diseases worldwide, closely related to gut microbiota. Various microbiota-related molecular and cellular mechanisms are involved in the progression of NAFLD, including dysbiosis, leaky bowel, endotoxin, bile acids enterohepatic circulation, and more.
Review
Food Science & Technology
Min Kyo Jeong, Byeong Hyun Min, Ye Rin Choi, Ji Ye Hyun, Hee Jin Park, Jung A. Eom, Sung Min Won, Jin Ju Jeong, Ki Kwang Oh, Haripriya Gupta, Raja Ganesan, Satya Priya Sharma, Sang Jun Yoon, Mi Ran Choi, Dong Joon Kim, Ki Tae Suk
Summary: Diet and lifestyle are crucial factors that affect the occurrence of NAFLD. Personalized diet patterns can influence the composition and activity of gut microbiota, exacerbating NAFLD via the gut-liver axis. Advances in diagnostic technology have improved the diagnosis, treatment, and prognosis of NAFLD. Microbiota-derived metabolites play a significant role in the pathogenesis of NAFLD.
Article
Gastroenterology & Hepatology
Ying Hong, Lili Sheng, Jing Zhong, Xin Tao, Weize Zhu, Junli Ma, Juan Yan, Aihua Zhao, Xiaojiao Zheng, Gaosong Wu, Bingbing Li, Bangxing Han, Kan Ding, Ningning Zheng, Wei Jia, Houkai Li
Summary: The study supports the use of herb-derived polysaccharides as prebiotics for treating NAFLD by modulating gut microbiome. It demonstrated the anti-NAFLD effect of Astragalus polysaccharides (APS) and the contribution of gut microbiota in HFD-fed mice. The results indicated that APS enriched bacteria such as D. vulgaris are effective in attenuating hepatic steatosis through producing acetic acid and modulating hepatic lipids metabolism.
Review
Gastroenterology & Hepatology
Meng -Yuan Wu, Jian-Gao Fan
Summary: Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease globally, causing a heavy economic burden. Gut dysbiosis plays a pivotal role in the development and progression of NAFLD, affecting gut permeability and allowing bacterial products to enter the liver. The gut microbiome may have potential as a non-invasive diagnostic tool and a novel therapeutic target for NAFLD.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
(2023)
Review
Gastroenterology & Hepatology
Alexandre Villard, Jerome Boursier, Ramaroson Andriantsitohaina
Summary: The liver and intestine communicate bidirectionally through the biliary tract, portal vein, and other components of the gut-liver axis. Imbalance in the gut bacterial community, known as dysbiosis, plays a key role in the development and progression of NAFLD by increasing the translocation of PAMPs in the blood. NAFLD development and progression are influenced by various factors.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
(2021)